2-Fluoro-benzoic acid 3-(2-benzenesulfonylamino-1,1-dimethyl-ethylamino)-2-hydroxy-propyl ester | 90531-73-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Fluoro-benzoic acid 3-(2-benzenesulfonylamino-1,1-dimethyl-ethylamino)-2-hydroxy-propyl ester
• 英文别名: [3-[[1-(Benzenesulfonamido)-2-methylpropan-2-yl]amino]-2-hydroxypropyl] 2-fluorobenzoate
• CAS: 90531-73-0
• 化学式: C₂₀H₂₅FN₂O₅S
• 分子量: 424.493
• InChiKey: YIFGOUGCEMURJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  29
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  邻氟苯甲酰氯 在 三乙胺 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 2-Fluoro-benzoic acid 3-(2-benzenesulfonylamino-1,1-dimethyl-ethylamino)-2-hydroxy-propyl ester
  参考文献：
  名称：

  [(Arylcarbonyl)oxy]propanolamines. 1. Novel .beta.-blockers with ultrashort duration of action

  摘要：

  Novel [(arylcarbonyl)oxy]propanolamines were synthesized and investigated as potential ultrashort-acting beta-adrenergic receptor blockers. Many of these analogues exhibited good potency and short duration. The N-ureidoalkyl analogue 85 (ACC-9089) has a potency equal to propranolol and a duration of action of about 21 min in the dog. It has been selected as a candidate for further clinical study. Structure-activity relationships and structure-duration relationships for these new beta-blockers are also discussed.

  DOI：

  10.1021/jm00374a013

文献信息

• EP0093765A4
  申请人：——

  公开号：EP0093765A4

  公开（公告）日：1984-04-27
• 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES
  申请人：AMERICAN HOSPITAL SUPPLY CORPORATION

  公开号：EP0093765A1

  公开（公告）日：1983-11-16
• [EN] 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES
  申请人：AMERICAN HOSPITAL SUPPLY CORPORATION

  公开号：WO1983001770A1

  公开（公告）日：1983-05-26

  (EN) Novel compounds of the general formula$(10,)$wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents -NR2COR1, -NR2CONR1R3, -NR2SO2R1, -NR2SO2NR1R3, or -NR2COOR1 wherein R1, R2 and R3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R1 is not hydrogen when B is -NR2SO2R1 or -NR2COOR1, or R1 and R3 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit beta-adrenergic blocking activity and are also useful in the treatment of glaucoma. (FR) Nouveaux composés de formule générale:$(10,)$où Ar représente un groupe aromatique ou hétérocyclique substitué ou non substitué; W représente un alkylène ayant de 1 à 10 atomes de carbone environ et B représente -NR2COR1, -NR2CONR1R3, -NR2SO2R1, -NR2SO2NR1R3, ou -NR2COOR1, où R1, R2 et R3 peuvent être identiques ou différents et peuvent représenter l'hydrogène, un alkyle, un alcoxy alkyle, un cycloalkyle, un alkényle, un alkynyle, un aryle, un hétéroaryle, ou un aralkyle, à l'exception que R1 ne représente pas l'hydrogène lorsque B représente -NR2SO2R1 ou -NR2COOR1, ou R1 et R3 peuvent former ensemble avec N un groupe hétérocyclique ayant de 5 à 7 membres; et leurs sels pharmaceutiquement acceptables. Ces composés ont une activité de blocage adrénergique beta et sont également utiles dans le traitement de glaucomes.
• [(Arylcarbonyl)oxy]propanolamines. 1. Novel .beta.-blockers with ultrashort duration of action
  作者：Sheung Tsam Kam、William L. Matier、Khuong X. Mai、Cynthia Barcelon-Yang、Robert J. Borgman、John P. O'Donnell、Herman F. Stampfli、Check Y. Sum、William G. Anderson

  DOI：10.1021/jm00374a013

  日期：1984.8

  Novel [(arylcarbonyl)oxy]propanolamines were synthesized and investigated as potential ultrashort-acting beta-adrenergic receptor blockers. Many of these analogues exhibited good potency and short duration. The N-ureidoalkyl analogue 85 (ACC-9089) has a potency equal to propranolol and a duration of action of about 21 min in the dog. It has been selected as a candidate for further clinical study. Structure-activity relationships and structure-duration relationships for these new beta-blockers are also discussed.